Posts

Posted on

Inpixon Acquires The CXApp, a Leading Smart Workplace App and Hybrid Events Solution Provider

Mobile App Development Platform Supports Digital Workplace Transformation, Events Management and Integrated Employee Experience to Meet Demands for the Future of Work

PR Newswire

PALO ALTO, Calif., May 3, 2021 /PRNewswire/ — Inpixon (Nasdaq: INPX), the Indoor Intelligence™ company, today announced it has acquired the outstanding capital stock of Design Reactor, Inc. (a.k.a., “The CXApp“), a leading SaaS app platform. The CXApp enables corporate enterprise organizations to provide a custom-branded, location-aware employee app focused on enhancing the workplace experience and hosting virtual and hybrid events. The acquisition is expected to be accretive to revenue and earnings. Leon Papkoff, founder of The CXApp, joins Inpixon as executive vice president leading Inpixon’s CXApp Division.

Inpixon and The CXApp have recently partnered on several enterprise engagements and are seeing strong demand for applications that enable smarter, safer and more secure workplaces. Businesses and employees are experiencing a paradigm shift in what it means to “go to work” and how employees interact with one another and the physical spaces that make up the workplace. The combined offerings and expertise of the companies provides customers with access to an unparalleled suite of complementary products, giving employees the ability to manage different types of workplace scenarios from their personal devices, and to have access to smarter, location-aware experiences. To meet the demand for rapid deployment, more than 75 pre-built integrations with third-party solutions are available, including Active Directory, Exchange, G-Suite, Zoom and Slack. 

With this acquisition, the two companies believe they will be able to move quicker and innovate faster than others in the space in order to capture a significant share of the global digital workplace market which is expected to grow from $22.7 billion in 2020 to $72.2 billion by 2026 at a CAGR of 21.3%, and the global event management software market which is forecasted to grow from $3.6 billion in 2020 to $6.4 billion by 2026 at a CAGR of 10.0% according to research firm MarketsandMarkets. 

“This acquisition of The CXApp and its fusion with Inpixon’s products, immediately with mapping and on-device positioning and in the near term with our sensors and tags, is a transformative step to grow our business significantly,” said Nadir Ali, CEO of Inpixon. “Due to the increasing need for technologies that can support the changing demands of a hybrid workplace, The CXApp has experienced over 73% in revenue growth in 2020 as compared to the prior year and an even greater increase in demand and pipeline growth, and we are seeing this rapid growth rate continue into 2021. As a combined solution, Inpixon expects to see an increase in average selling price (ASP) by 10x over its existing mapping products currently offered to enterprise organizations, which we anticipate will result in substantial revenue growth. The CXApp’s platform for multi-location, live-streamed and on-demand events is another key market need addressed by Inpixon as a result of the acquisition. Leveraging The CXApp’s event management platform for the booming hybrid events category could further increase the expected revenues and help us to achieve added valuation metrics for this product line reflective of events companies recently, such as Hopin and Bizzabo.”

Leon Papkoff, EVP, Inpixon’s CXApp Division, stated, “With nearly one million end-user profiles deployed globally across a dozen countries, The CXApp has pioneered workplace technology for the last six years, leading innovative experiences across employee engagement, office solutions, and desk booking technology for Fortune 500 and other enterprise customers in high tech, healthcare, media, retail, and financial services. We are pleased to have joined Inpixon, and we look forward to continuing the mutual success with our great ecosystem partners as we help businesses bring their employees back to the office in a safe and efficient manner that carries over well beyond the pandemic.”

Soumya Das, COO of Inpixon, commented, “Inpixon is an innovator in the Indoor Intelligence space. We believe we were first to market with RF sensor fusion including UWB, Wi-Fi, BLE and cellular detection and positioning, displaying simultaneous RF and video integration, and incorporating artificial intelligence into positioning analytics. We’ve continued that leadership with our integration of indoor mapping and on-device blue dot tracking, and we recently added augmented reality – a technology with the potential to favorably disrupt the market – to our portfolio to support more immersive user experiences. And now with The CXApp, we can offer what we believe is the market’s only enterprise-class SaaS-based mobile app platform for workplace transformation and events management with deep integration of advanced mapping and positioning capabilities. We welcome The CXApp employees, customers and partners to the Inpixon team and look forward to continuing to fulfill our mission to do good with indoor data.”

Answers to frequently asked questions about this announcement can be found on the FAQ available here.

The acquisition consists of a purchase price that includes a combination of cash and equity. For additional details concerning the terms of the transaction, please reference the Company’s current report on Form 8-K which will be filed with the U.S. Securities and Exchange Commission.

About The CXApp

The CXApp is a mobile solution for digital workplace experience, built on a SaaS platform, driving mobile-first engagement through personalized and connected on-site journeys. The CXApp is a leading mobile app platform that can be customized and deployed across all of an organization’s locations, buildings, and programs year after year. The CXApp streamlines all digital touchpoints across the workplace into one central hub. For more information, visit thecxapp.com.

About Inpixon

Inpixon® (Nasdaq: INPX) is the Indoor Intelligence™ company that specializes in capturing, interpreting and giving context to indoor data so it can be translated into actionable intelligence. The company’s Indoor Intelligence platform ingests diverse data from IoT, third-party and proprietary sensors designed to detect and position active cellular, Wi-Fi, UWB and Bluetooth devices. Paired with a high-performance data analytics engine, patented algorithms, and advanced mapping technology, Inpixon’s solutions are leveraged by a multitude of industries to do good with indoor data. This multidisciplinary depiction of indoor data enables users to increase revenue, decrease costs, and enhance safety. Inpixon customers can boldly take advantage of location awareness, analytics, sensor fusion and the Internet of Things (IoT) to uncover the untold stories of the indoors. For the latest insights, follow Inpixon on LinkedIn, Twitter, and visit inpixon.com.

Safe Harbor Statement

All statements in this release that are not based on historical fact are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of the control of Inpixon and its subsidiaries, which could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not limited to, the fluctuation of economic conditions, the impact of COVID-19 on Inpixon’s results of operations, Inpixon’s ability to integrate the products and business from The CXApp and other recent acquisitions into its existing business, the performance of management and employees, the regulatory landscape as it relates to privacy regulations and their applicability to Inpixon’s technology, Inpixon’s ability to maintain compliance with Nasdaq’s minimum bid price requirement and other continued listing requirements, the ability to obtain financing, competition, general economic conditions and other factors that are detailed in Inpixon’s periodic and current reports available for review at sec.gov. Furthermore, Inpixon operates in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. Inpixon disclaims any intention to, and undertakes no obligation to, update or revise forward-looking statements.

Inpixon Contacts

Media relations and general inquiries:

Inpixon
Email: [email protected]
Web: inpixon.com/contact-us

Investor relations:

Crescendo Communications, LLC
Tel: +1 212-671-1020
Email: [email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/inpixon-acquires-the-cxapp-a-leading-smart-workplace-app-and-hybrid-events-solution-provider-301281868.html

SOURCE Inpixon

Posted on

Boston Scientific Announces May Conference Schedule

PR Newswire

MARLBOROUGH, Mass., (May 3, 2021 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.

On May 11, 2021, Dan Brennan, executive vice president and chief financial officer, and Susie Lisa, vice president, Investor Relations, will participate in a 35-minute question-and-answer session with the host analyst at the virtual 2021 Bank of America Health Care Conference. The session will begin at approximately 9:30 a.m. EDT.

On May 25, 2021, Jeff Mirviss, executive vice president and president, Peripheral Interventions; Peter Pattison, president, Interventional Oncology, Peripheral Interventions; Cat Jennings, vice president, marketing and new business development, Peripheral Interventions; and Susie Lisa will participate in a 45-minute question-and-answer session with the host analyst at the 2021 UBS Global Healthcare Virtual Conference. The session will begin at approximately 9 a.m. EDT.

A live webcast and replay of the webcast for each event will be accessible at investors.bostonscientific.com.  The replay will be available beginning approximately one hour following the completion of each event.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.


CONTACTS

Media:

Investors:

Katie Schur

Susie Lisa, CFA

508-683-5574 (office)

508-683-5565 (office)

Media Relations

Investor Relations

Boston Scientific Corporation

Boston Scientific Corporation


[email protected] 


[email protected]

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/boston-scientific-announces-may-conference-schedule-301281924.html

SOURCE Boston Scientific Corporation

Posted on

Precipio Launches its Rapid COVID-19 Antibody test on Amazon Platform

Nirmidas’ test is available to POC healthcare providers with an Amazon business account

NEW HAVEN, Conn., May 03, 2021 (GLOBE NEWSWIRE) — Specialty diagnostics company Precipio, Inc.(NASDAQ: PRPO), announced that it has successfully launched its COVID-19 rapid antibody test (20 minute) which tests for both IgG & IgM antibodies, on Amazon.com’s business platform. Precipio holds the exclusive rights to distribute this product on Amazon’s platform. The antibody test, which is manufactured in the USA by Nirmidas Biotech, of California, was the first US-based test to receive emergency use authorization (EUA) by the FDA for point-of-care.

The product is visible for sale on Amazon’s website and app (click here), per the EUA approval received for the test kit in December of 2020; however it may currently be purchased only by qualified medical point-of-care (POC) providers. Physicians and other medical facilities may now purchase these items directly from Amazon, and receive them within 2 business days.

Clinical Utility of the COVID-19 Antibody Test

The purpose of this test is to identify the presence of antibodies that have been developed after the person has been exposed to the virus, or has been vaccinated. Antibodies are the body’s natural biological response to an infection or vaccination, and their development begins the body’s process of building immunity to protect against future infections.

There are two key important benefits to knowing if an individual has antibodies. First, individuals unknowingly infected or those who know they were infected can determine if they now have those antibodies. For those who are deliberating whether to get vaccinated, this test presents a tool that can provide additional information to make that decision. Secondly, individuals who have been vaccinated can use the test to inform whether the vaccination was successful and if the antibodies measured have persisted over time.

“We are very excited to be working with our partner Nirmidas to get this important rapid test on the largest retail platform in the world,” said Ilan Danieli, Precipio’s Chief Executive Officer. “We look forward to working with other retail outlets, as well as with Nirmidas to advance this product into at-home use, following the receipt of appropriate FDA authorization”.

About Precipio

Precipio has built a platform designed to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions and delivering quality diagnostic information to physicians and their patients worldwide, as well as proprietary products that serve laboratories worldwide. Through its collaborations with world-class academic institutions specializing in cancer research, diagnostics and treatment such as the Yale School of Medicine, Harvard’s Dana-Farber Cancer Institute, and the University of Pennsylvania, Precipio offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.

Please follow us on Twitter @PrecipioDx and on Facebook. 

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, among others, statements related to the expected or potential impact of the novel coronavirus (COVID-19) pandemic, and the related responses of the government, consumers, and the Company, on our business, financial condition and results of operations, and any such forward-looking statements, whether concerning the COVID-19 pandemic or otherwise, involve risks, assumptions and uncertainties. Except for historical information, statements about future volumes, sales, growth, costs, cost savings, margins, earnings, earnings per share, diluted earnings per share, cash flows, plans, objectives, expectations, growth or profitability are forward-looking statements based on management’s estimates, beliefs, assumptions and projections. Words such as “could,” “may,” “expects,” “anticipates,” “will,” “targets,” “goals,” “projects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “predicts,” and variations on such words, and similar expressions that reflect our current views with respect to future events and operational, economic and financial performance, are intended to identify such forward-looking statements. These forward-looking statements are only predictions, subject to risks and uncertainties, and actual results could differ materially from those discussed. Important factors that could affect performance and cause results to differ materially from management’s expectations, or could affect the Company’s ability to achieve its strategic goals, include the uncertainties relating to the impact of COVID-19 on the Company’s business, operations and employees and the other factors that are described in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis” in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2020, as updated from time to time in the Company’s Securities and Exchange Commission filings.

The Company’s forward-looking statements in this press release are based on management’s current views, beliefs, assumptions and expectations regarding future events and speak only as of the date of this release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by the federal securities laws.



Inquiries:

[email protected]

+1-203-787-7888 Ext. 523

Posted on

PAVmed to Hold Business Update Conference Call on May 17, 2021

Company conference call and webcast at 4:30 PM EDT

NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) — PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that the Company will host a business update conference call on Monday, May 17, 2021 at 4:30 PM EDT. During the call, Lishan Aklog, M.D., Chairman and Chief Executive Officer of the Company, will provide a business update including an overview of the Company’s near-term milestones and growth strategy. In addition, Dennis McGrath, the Company’s President and Chief Financial Officer, will discuss first quarter 2021 financial results.

To access the conference call, U.S.-based listeners should dial (877) 407-3982 and international listeners should dial (201) 493-6780. All listeners should provide the operator with the conference call name “PAVmed, Inc. Business Update Conference Call” to join. Individuals interested in listening to the live conference call via webcast may do so by visiting the investor relations section of the Company’s website at www.pavmed.com.

Following the conclusion of the conference call, a replay will be available for one week and can be accessed by dialing (844) 512-2921 from within the U.S. or (412) 317-6671 from outside the U.S. To access the replay, all listeners should provide the following pin number: 13719121. The webcast will be available for replay on the investor relations section of the Company’s website at www.pavmed.com.

About PAVmed
 and Lucid

PAVmed Inc. is a highly differentiated, multi-product, commercial-stage medical technology company with a diversified product pipeline addressing unmet clinical needs encompassing a broad spectrum of clinical areas with attractive regulatory pathways and market opportunities. Its major subsidiary, Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. Its GI Health division also includes the complementary EsoCure™ Esophageal Ablation Device with Caldus™ Technology. Its Minimally Invasive Interventions markets its CarpX® Minimally Invasive Device for Carpal Tunnel Syndrome. Other divisions include Infusion Therapy (PortIO™ Implantable Intraosseus Vascular Access Device and NextFlo™ Intravenous Infusion Set), and Emerging Innovations (non-invasive laser-based glucose monitoring, pediatric ear tubes, and mechanical circulatory support). For more information, please visit www.pavmed.com, follow us on Twitter, connect with us on LinkedIn, and watch our videos on YouTube. For more information on our majority owned subsidiary, Lucid Diagnostics Inc., please visit www.luciddx.com, follow Lucid on Twitter, and connect with Lucid on LinkedIn. For detailed information on EsoGuard, please visit www.EsoGuard.com and follow us on Twitter, Facebook and Instagram.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements, based upon the current beliefs and expectations of PAVmed’s management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of PAVmed’s common stock, Series W Warrants and Series Z Warrants; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required advance PAVmed’s products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from PAVmed’s preclinical studies; whether and when PAVmed’s products are cleared by regulatory authorities; market acceptance of PAVmed’s products once cleared and commercialized; our ability to raise additional funding and other competitive developments. PAVmed has not yet received clearance from the FDA or other regulatory body to market many of its products. The Company has been monitoring the COVID-19 pandemic and its impact on our business. The Company expects the significance of the COVID-19 pandemic, including the extent of its effect on the Company’s financial and operational results, to be dictated by, among other things, the success of efforts to contain it and the impact of actions taken in response. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond PAVmed’s control. For a further list and description of these and other important risks and uncertainties that may affect PAVmed’s future operations, see Part I, Item IA, “Risk Factors,” in PAVmed’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, “Risk Factors” in any Quarterly Report on Form 10-Q filed by PAVmed after its most recent Annual Report. PAVmed disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

Contacts:

Investors

Mike Havrilla
Director of Investor Relations
(814) 241-4138
JMH@PAVmed.com

Media

Shaun O’Neil
Chief Commercial Officer
(518) 812-3087
[email protected]

Jim Heins / Katie Gallagher
LaVoieHealthScience
(646) 491-7042 / (617) 792-3937
[email protected]



Posted on

iBrands Corporation Becomes Product Sponsor For Professional Football Franchise

LAS VEGAS, May 03, 2021 (GLOBE NEWSWIRE) — iBrands Corporation (OTC PINK: IBRC) (“the Company”), a diversified holding and branding company, announces that through its subsidiary iBrands Farms, has become a product sponsor for the Ontario Bandits Football Club, respectively.

The Ontario Bandits became the newest expansion team for the National Arena League (NAL) as the league previously announced recent expansion with the Albany Empire as its New York based franchise this previous October. The Bandits will be the seventh team entering the 2021 season with the NAL joining the Jacksonville Sharks, Columbus Lions, Carolina Cobras, Orlando Predators, Jersey Flight, and the Albany Empire.

The company will be providing its immune boosting nutraceutical supplement QuadraMune to the players and staff of the Ontario Bandits as the state of California begins its gradual reopening.

QuadraMune™ is a nutritional supplement which has previously been demonstrated to possess anti-inflammatory and immune modulatory activity based on in vitro and pilot in vivo studies. The current clinical trial aims to assess in a 500 volunteer trial the efficacy of QuadraMune™ in reducing infection in individuals at high risk of COVID-19.

iBrands Corporation entered into a Master Sales Agreement with Therapeutic Solutions Inc. (“TSOI”) to distribute the nutraceutical line of products developed by TSOI for sales through its iBrands Farms subsidiary.

Products to be included in the Master Sales Agreement currently consist of NanoStilbene, NanoPSA, Nano Plus, Nano Cannabidiol, ProJuvenol, and Immune Booster QuadraMune.

A clinical trial has been granted ClinicalTrials.gov Identifier: NCT04421391 and is now on the Federal Clinical Trial registry: https://www.clinicaltrials.gov/ct2/show/NCT04421391.

Other exciting developments from this license include the public information release from TSOI includes “QuadraMune Reduces Myeloid Suppressor Cells in 4T1 Mouse Model of Breast Cancer New Patent Filing Suggests Novel Mechanism of Immune Boosting Nutraceutical Can Augment Efficacy of Cancer Immunotherapy.” and, “Positive QuadraMune™ Clinical Trial Data,” which suggests data from its clinical trial demonstrating an almost doubling of immune cell activity in healthy volunteers which were ingesting QuadraMune™ daily for a week.

Investigators analyzed blood for production of an immunological protein called “interleukin-2” after stimulation with anti-CD3 and anti-CD28. The substantial increase in interleukin-2 is believed to predict that immunological cells such as T cells and NK cells, which are needed to fight viruses such as SARS-CoV-2, possess enhanced function after QuadraMune™ administration.

Currently the Company is running a clinical trial on QuadraMune™ for preventing COVID-19 in health care workers. The clinical trial is listed on the National Institutes of Health Clinical Trial Database at www.clinicaltrials.gov.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.

About the Ontario Bandits Football Club

The Ontario Bandits Football Club is a sports and entertainment property located in Southern California that is committed to exhibiting hard work and excellence both on the field and off in our respective communities.

For more information please go to: https://www.toyota-arena.com/teams/detail/ontario-bandits
https://www.ontariobandits.com/

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. The Company’s corporate website is at www.therapeuticsolutionsint.com and our e-commerce is at www.youcanordernow.com and for additional info on NanoStilbene visit www.nanostilbene.com.

About iBrands Farms

iBrands Farms is a vertically integrated agribusiness focused on the production and sale of products with naturally occurring cannabinoids. Our mission is to efficiently deliver the highest quality industrial hemp-derived cannabinoid products and unique nutraceuticals to our customers, both retail and wholesale. The company can be found at www.ibrandsfarms.com

About iBrands Corporation

iBrands Corporation, Inc. is a holding and branding company that acquires and operates niche market brands that have unique market positions within sectors that demonstrate return on investment potential. Business partnerships throughout the United States and Canada provide our brands many markets to expand into and produce consistently high growth rates for the next decade. The company can be found at: www.ibrandscorporation.com

Safe Harbor Statement

This release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E and/or 27E of the Securities Exchange Act of 1934 that are based upon assumptions that in the future may prove not to have been accurate and are subject to significant risks and uncertainties, including statements as to the future performance of the company and the risks and uncertainties detailed from time to time in reports filed by the company with the Securities and Exchange Commission. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations or any of its forward-looking statements will prove to be correct. Factors that could cause results to differ include, but are not limited to, the company’s ability to raise necessary financing, retention of key personnel, timely delivery of inventory from the company’s suppliers, timely product development, product acceptance, and the impact of competitive services and products, in addition to general economic risks and uncertainties.

Sources:


https://www.globenewswire.com/news-release/2020/11/17/2128654/0/en/Ontario-Bandits-Football-Club-Joins-National-Arena-League.html


https://www.nationalarenaleague.com/


https://www.twincities.com/2021/03/05/california-to-let-major-league-baseball-disneyland-reopen/


https://ballparkdigest.com/2021/03/08/california-mlb-teams-cleared-for-fans-in-the-stands/


https://www.latimes.com/california/story/2021-05-01/minimal-vaccine-hesitancy-fuels-californias-covid-recovery


https://www.yahoo.com/lifestyle/ibrands-corporation-adds-immune-booster-131010087.html


https://www.globenewswire.com/news-release/2020/06/17/2049529/0/en/iBrands-Corporation-Announces-Clinical-Trial-For-Immune-Booster-Product.html


https://www.marketscreener.com/IBRANDS-CORP-13534846/news/iBrands-Corporation-Reports-QuadraMune-Reduces-Myeloid-Suppressor-Cells-in-4T1-Mouse-Model-of-Breast-30805640/?utm_medium=RSS&utm_source=googlenews&utm_content=20200622


https://www.nasdaq.com/press-release/ibrands-corporation-reports-reduction-of-brain-inflammation-depression-associated
 



For more information please contact:

[email protected]

Posted on

Schneider vice president named a 2021 “Pro to Know” by Supply & Demand Chain Executive

Mike Kukiela is recognized for excellence in leveraging supply chain for competitive advantage.

Green Bay, Wis., May 03, 2021 (GLOBE NEWSWIRE) — Mike Kukiela, senior vice president of Supply Chain and Distribution Management at Schneider, (NYSE: SNDR), a premier provider of trucking, intermodal and logistics services, has been named one of Supply & Demand Chain Executive’s 2021 “Pros to Know.” This award recognizes outstanding executives whose accomplishments leverage supply chains for competitive advantage.

This year’s list of “Pros to Know” recognizes individuals and teams from a multitude of industries, including trucking and transportation firms, who have helped supply chain clients and the supply chain community at large prepare to meet many of today’s – and tomorrow’s – challenges.

Kukiela leads the development of logistics solutions that deliver measurable value to the most complex supply chain through technology, processes and procedures. Under his leadership, he helped Schneider launch three initiatives to help customers achieve resiliency during the COVID-19 pandemic.

“The pandemic presented our team with many challenges, as well as opportunities to find innovative solutions,” said Kukiela. “I have enjoyed working with the incredible thought leaders at Schneider and being able to drive positive results for our business partners.”

Schneider has benefited immensely from Kukiela’s dedicated leadership for nearly 17 years. In addition to his passion for supply chain, he strives to develop associates with diverse backgrounds and varying levels of experience to leadership roles within the company. He believes the workforce must reflect society.

“A diverse workforce helps fuel innovative thinking,” said Kukiela. “Working at Schneider, I have been able to collaborate with leaders from several backgrounds, which has made all the difference in solving our customers’ complex challenges.”

Learn more about Schneider and the company’s innovative shipping and transportation solutions.

About Schneider 

Schneider is a premier provider of transportation and logistics services. Offering one of the broadest portfolios in the industry, Schneider’s solutions include Regional and Long-HaulTruckload, Expedited, Dedicated, Bulk, Intermodal, Brokerage, Warehousing, Supply Chain Management, Port Logistics and Logistics Consulting.

With $4.6 billion in annual revenue, Schneider has been safely delivering superior customer experiences and investing in innovation for over 85 years. The company’s digital marketplace, Schneider FreightPower®, is revolutionizing the industry giving shippers access to an expanded, highly flexible capacity network and provides carriers with unmatched access to quality drop-and-hook freight – Always Delivering, Always Ahead.

For more information about Schneider, visit Schneider.com or follow the company socially on Facebook,LinkedIn and Twitter: @WeAreSchneider.

Source: Schneider SNDR

 

-END-

Attachments 



Kara Leiterman
Schneider 
920-370-7188
[email protected]

Posted on

German Lifestyle Store Returns to Celebros Search by Bridgeline

WOBURN, Mass., May 03, 2021 (GLOBE NEWSWIRE) — Bridgeline Digital, Inc. (NASDAQ: BLIN), provider of cloud-based marketing technology software, announced a German provider of athleticwear and fashion is once again choosing Celebros to perfect their online experience.

This business has over 70 years’ experience in trading history, with a unique mix of assortments that builds bridges between sport and leisure, job and lifestyle. They claim a very special position in the retail landscape with their commitment to current, high-quality fashion and functional sports and outdoor equipment. With their five online shops, the retailer offers a wide spectrum of products for a massive and diverse German audience.

This business was a Celebros client until a few years ago when they re-platformed. Recently, the digital team decided to research the best site search providers available. The team was delighted to rediscover Celebros, an eCommerce approach designed to help users navigate and purchase from the company’s website with ease and efficiency. The high search quality, excellent service and warm and established relationship, alongside a great pricing strategy, allowed Celebros to stand out against a crowded European competitive landscape.

“We are always excited when a former customer comes back to us after restructuring their website,” said Ari Kahn, President and CEO of Bridgeline Digital. “It’s encouraging to know that we are still among the best intelligent site search providers and we can’t wait to implement innovative solutions for this customer.” 

About Bridgeline Digital 

Bridgeline helps companies grow online revenues by increasing their traffic, conversion rates, and average order values with its Unbound cloud-based marketing platform and suite of apps. To learn more, please visit www.bridgeline.com or call (800) 603-9936.

Contact: 
Jeremy LaDuque 
EVP of Marketing 
Bridgeline Digital 
[email protected] 



Posted on

Disconnect between increased stress and lower diagnoses rates raises concerns

Disconnect between increased stress and lower diagnoses rates raises concerns

Pandemic leads to decrease in mental healthcare over 2020 calendar year for children and older adults, says State of the Nation’s Mental Health report

INDIANAPOLIS–(BUSINESS WIRE)–
While people in America have shared that the pandemic and other stressors like social injustice, elections, and the economy negatively impacted their mental health in 2020, there wasn’t a corresponding increase in people seeking mental health treatment, according to the inaugural Anthem, Inc. State of the Nation’s Mental Health report.

However, diagnoses and treatment for anxiety and PTSD for adults were among the few mental health diagnoses that grew in 2020. Children and older adults appeared to have the largest overall downturn, reporting significantly fewer mental health diagnoses in 2020 compared to 2019. Younger adults, meanwhile, had a smaller than expected increase in mental health diagnoses for the full year of 2020.

These findings, part of a new State of the Nation’s Mental Health report based on Anthem affiliated health plan claims from 27 million Americans, show the pandemic disconnect between feeling stressed and depressed and being diagnosed and seeking treatment.

Recent studies have shown that many more adults reported symptoms of anxiety or depression. Further, 42 percent of people under 30 years old were experiencing anxiety and depression symptoms, according to a CDC survey from August 2020 through February 2021.

“What this says to us is that there are many people who may benefit from mental health services, especially children and older adults, who either aren’t being identified or aren’t reaching out to get the help they might need,” said Anthem Chief Health Officer Shantanu Agrawal, M.D. “This is a call out for all of us. We don’t hesitate to help others get the COVID-19 vaccine to protect themselves from the virus and we shouldn’t hesitate to help people find the mental health services they need as they cope with the pandemic, which is equally important to their overall health. That’s why we are dedicated to increasing our focus on whole health.”

The results of the study are supported by other Anthem data from IngenioRx, its pharmacy benefits manager. While the overall utilization for medications to treat depression was up in 2020, much of that increase can be attributed to existing users being more adherent to their dosing regimens, according to IngenioRx medication adherence data. New users of these medications increased at the same rate as 2019.

The State of the Nation’s Mental Health report showed the following drops in 2020 rates for those treated for mental health diagnoses compared to those treated in 2019:

  • 10 percent overall drop for young children
  • 5 percent overall drop for adolescents
  • 5 percent overall drop for adults older than 75
  • 13 percent drop for young children diagnosed with ADHD
  • 8 percent drop for adolescents diagnosed with ADHD
  • 8 percent drop in adults older than 75 diagnosed with dementia, and a
  • 3 percent drop for both Baby Boomers and adults older than 75 diagnosed for depression.

“While we don’t know for sure why children and older adults had fewer diagnoses, we speculate that they weren’t interacting as often with people in our communities who have increasingly become the starting point for mental health diagnoses,” said Agrawal. “Children involved in distance learning had less face time with teachers, who often recommend testing for mental health or attention concerns, and older adults may not have been able or were more reluctant to see their primary care provider in 2020, which may play a role in the decrease in dementia diagnoses, and perhaps, decreased diagnoses for depression.”

Nearly three out of four mental health specialists and primary care doctors estimated in an Anthem commissioned survey that mental health repercussions from the virus will last up to three years or longer and almost two-thirds believe their patients’ mental health declined in the second half of the pandemic (September 2020-February 2021) compared to the first half (March-August 2020).

“When people encounter more stress, it’s logical to expect trends for mental health diagnoses to increase. However, for many, such as children who may be learning virtually and isolated seniors — that hasn’t been the case,” said Agrawal. “This subsequent ‘mental health’ pandemic could have impacts for years to come, reinforcing the need for mental health and physical health to be addressed equally and simultaneously.”

On a positive note, nine out of 10 healthcare professionals surveyed said that COVID-19 has made them more aware of the mental health conditions their patients are experiencing. Seventy percent of healthcare professionals said their patients have been more willing to proactively bring up mental health concerns during appointments.

A majority of healthcare professionals said that patients who were already seeking therapy or in a support group prior to the start of the pandemic have more successfully coped with their mental health concerns. And, many noted they are seeing an increased emphasis in patient self-care and better work/life flexibility.

“People in general and young people in particular should not be reluctant to seek mental health help when they need it,” said Paul Gionfriddo, President and CEO of Mental Health America, the nation’s largest mental health advocacy organization. “We know from the millions of help-seeking people who have reached out to us this past year that more people than ever are in need of help, and we want them to know that it is a show of strength, not weakness, to seek that help as early as possible, and the first step on the pathway to recovery.”

Information about how to recognize the signs and symptoms of mental health conditions is available at the State of the Nation’s Mental Health report web site and the Mental Health America web site.

Survey and Claims Methodology

The State of the Nation’s Mental Health report is based on claims data from 27 million members in Anthem affiliated individual, employer-sponsored, Medicare and Medicaid health plans in all states. Prevalence of behavioral health diagnoses each year (2019 and 2020) was determined by the number of individuals with at least one claim containing a behavioral health diagnosis during the calendar year divided by the number of members enrolled in the plans.

The Anthem online survey was conducted among a national sample consisting of 552 healthcare professionals, broken out into 285 behavioral health specialists and 267 primary care physicians/general practitioners living in the United States, with an oversample of 100 rural healthcare professionals. The sample includes a diverse set of respondents across key demographics (age, gender, region, race/ethnicity) and experience as a physician (time spent in practice, type of practice, size of practice). The margin of error for the total sample at the 95 percent confidence level is +/- 4 percentage points.

About Anthem, Inc.

Anthem is a leading health benefits company dedicated to improving lives and communities, and making healthcare simpler. Through its affiliated companies, Anthem serves more than 116 million people, including more than 43 million within its family of health plans. We aim to be the most innovative, valuable and inclusive partner. For more information, please visit www.antheminc.com or follow @AnthemInc on Twitter.

Lori McLaughlin, 317.407.7403, [email protected]

KEYWORDS: United States North America Indiana

INDUSTRY KEYWORDS: Professional Services Mental Health Other Consumer Health Consumer Insurance

MEDIA:

Posted on

IQST – iQSTEL Prepares To Launch Mobile Number Portability Application Blockchain Platform

PR Newswire

NEW YORK, May 3, 2021 /PRNewswire/ — iQSTEL, Inc. (USOTC: IQST) today announced completing the backend development for the Mobile Number Portability Application (MPNA) Blockchain Platform. The Platform has been fully tested and is ready to go.

The MNPA allows a Mobile End User to easily and quickly change form one Mobile Network Carrier to another in just 3 clicks. No days long dealing with a service provider anymore.

iQSTEL’s MNPA is anticipated to be an industry gamechanger as it allows Mobile Users to seamlessly change from one Mobile Network Carrier to another.

The initial estimation of the MNPA Platform as a Service (PaaS) market size is approximately $260 million annually. iQSTEL’s ItsBchain subsidiary is targeting a 10% MNPA market capture within the next three years.

The Company’s long-term goal is to implement the MNPA PaaS, or as we like to say, Blockchain as a Service (BaaS), with over one billion end users.

Our MNPA BaaS will include smart contract functionality and as part of the Blockchain platform, our MNPA will also include a high degree of protection for end user information. 

We are working on the marketing material now in preparation for the market launch of the MPNA service. The market launch is slightly delayed (2-3 weeks) from the original April target launch date due to project execution issues resulting from the impact of the Covid-19 crisis in India.

The MNPA is a product of iQSTEL’s Blockchain platform development subsidiary, ItsBchain (www.itsBchain.com).

As we prepare to rollout the MPNA service, we want to thank www.Cynopia.com for all your support and professional work in the development of all iQSTEL – Blockchain platforms.

About iQSTEL Inc.:

iQSTEL Inc (OTC: IQST) (www.iQSTEL.com) is a US-based publicly-listed company offering leading-edge Telecommunication, Technology and Fintech Services for Global Markets, with presence in 13 countries. The company provides services to the Telecommunications, Electric Vehicle (EV), Liquid Fuel Distribution, Chemical and Financial Services Industries. iQSTEL has 4 Business Divisions: Telecom, Technology, Fintech and Blockchain, with worldwide B2B and B2C customer relations operating through its subsidiaries: Etelix, SwissLink, QGlobal SMS, SMSDirectos, IoT Labs, Global Money One and itsBchain. The Company has an extensive portfolio of products and services for its clients: SMS, VoIP, 4G & 5G international infrastructure connectivity, Cloud-PBX, OmniChannel Marketing, IoT Smart Electric Vehicle Platform, iQ Batteries for Electric Vehicles, IoT Smart Gas Platform, IoT Smart Tank Platform, Visa Debit Card, Money Remittance, Mobile Number Portability Application MNPA (Blockchain Platform) and Settlement & Payments Marketplace (Blockchain Platform).

Safe Harbor Statement: Statements in this news release may be “forward-looking statements”. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date of this news release and iQSTEL Inc. undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this news release.

Logo – https://mma.prnewswire.com/media/1308745/iQSTEL_Logo.jpg

iQSTEL Inc.
IR US Phone: +1-646-740-0907, IR Email: [email protected]
iQSTEL Inc. and its subsidiaries: www.iqstel.com 

Cision View original content:http://www.prnewswire.com/news-releases/iqst–iqstel-prepares-to-launch-mobile-number-portability-application-blockchain-platform-301282167.html

SOURCE iQSTEL, Inc.

Posted on

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Continues to Investigate MRLN, PFPT, GRA, RMRM; Shareholders are Encouraged to Contact the Firm

NEW YORK, May 03, 2021 (GLOBE NEWSWIRE) — Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:


Marlin Business Services Corp. (NASDAQ: MRLN)
 concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to HPS Investment Partners LLC for $23.50 per share. If you are a Marlin Business shareholder, click here to learn more about your rights and options.


Proofpoint, Inc. (NASDAQ: PFPT)
 concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Thoma Bravo for $176.00 per share in cash. If you are a Proofpoint shareholder, click here to learn more about your rights and options.


W. R. Grace & Co. (NYSE: GRA)
 concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Standard Industries Holdings Inc. for $70.00 per share in cash. If you are a W. R. Grace shareholder, click here to learn more about your rights and options.


RMR Mortgage Trust (NASDAQ: RMRM)
 concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Tremont Mortgage Trust. RMR Mortgage is expected to issue common stock in connection with the merger. If you are an RMR Mortgage shareholder, click here to learn more about your rights and options.

Halper Sadeh LLP may seek increased consideration, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.

Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected].

Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLP
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]  
https://www.halpersadeh.com